Vimarsana
Biggest News Aggregation in the World

Page 2 - Pharma Partnering News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pharma Partnering. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pharma Partnering Today - Breaking & Trending Today

Artax Biopharma Appoints Andre Hoekema, Ph.D., to Company's Board of Directors - Vimarsana News

Artax Biopharma Appoints Andre Hoekema, Ph.D., to Company's Board of Directors

/PRNewswire/ -- Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T-cell-mediated diseases, today...

EBD Group: BIO-Europe Spring 2023 is Only a Few Weeks Away - Vimarsana News

EBD Group: BIO-Europe Spring 2023 is Only a Few Weeks Away

MUNICH, GERMANY / ACCESSWIRE / March 6, 2023 / EBD Group is thrilled to reunite on March 20-22, 2023 in Basel, Switzerland. After being held digitally for the last three years, leading executives from

EQS-News: BIO-Europe Spring® 2023 is only a few weeks away - Vimarsana News

EQS-News: BIO-Europe Spring® 2023 is only a few weeks away

EQS-News: EBD Group / Key word(s): Conference BIO-Europe Spring® 2023 is only a few weeks away 06.03.2023 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE BIO-Europe Spring® 2023 is only a few weeks away Munich, Germany – March 6, 2023. EBD Gr...

Enterome's Management Attending Upcoming Meetings - Vimarsana News

Enterome's Management Attending Upcoming Meetings

PARIS, Oct. 11, 2022 /PRNewswire/ -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform

Roche To Buy Good Therapeutics Conditionally Active PD-1-regulated IL-2 Program - Vimarsana News

Roche To Buy Good Therapeutics Conditionally Active PD-1-regulated IL-2 Program

SOUTH SAN FRANCISCO (dpa-AFX) - Good Therapeutics Wednesday said Roche Holding AG (RHHBY) has agreed to acquire Good Therapeutics' conditionally active PD-1-regulated IL-2 Program.The deal also